Analysts expect that AngioDynamics, Inc. (NASDAQ:ANGO) will announce earnings of $0.02 per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for AngioDynamics’ earnings. The lowest EPS estimate is $0.01 and the highest is $0.02. AngioDynamics reported earnings per share of $0.22 during the same quarter last year, which indicates a negative year over year growth rate of 90.9%. The company is expected to report its next quarterly earnings results on Friday, January 3rd.
According to Zacks, analysts expect that AngioDynamics will report full-year earnings of $0.12 per share for the current year. For the next fiscal year, analysts anticipate that the company will post earnings of $0.30 per share, with EPS estimates ranging from $0.29 to $0.30. Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for AngioDynamics.
AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported $0.08 EPS for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.04. AngioDynamics had a return on equity of 4.89% and a net margin of 17.79%. The firm had revenue of $66.00 million for the quarter, compared to analyst estimates of $67.74 million. During the same quarter last year, the company earned $0.16 EPS. The company’s revenue was up 3.3% on a year-over-year basis.
ANGO has been the subject of several research analyst reports. BidaskClub lowered AngioDynamics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, October 8th. TheStreet lowered AngioDynamics from a “c” rating to a “d+” rating in a research report on Thursday, October 3rd. KeyCorp lowered their price objective on AngioDynamics from $30.00 to $21.00 and set an “overweight” rating for the company in a research report on Friday, October 4th. Finally, ValuEngine raised AngioDynamics from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. AngioDynamics currently has an average rating of “Hold” and an average price target of $21.33.
Shares of ANGO stock traded up $0.08 during trading hours on Friday, reaching $15.09. The company’s stock had a trading volume of 228,900 shares, compared to its average volume of 235,403. The firm’s 50 day simple moving average is $15.76 and its 200-day simple moving average is $18.69. AngioDynamics has a fifty-two week low of $13.72 and a fifty-two week high of $25.48. The company has a market capitalization of $568.81 million, a price-to-earnings ratio of 18.18 and a beta of 0.63.
In other AngioDynamics news, CEO James C. Clemmer acquired 15,000 shares of the stock in a transaction dated Friday, October 25th. The stock was purchased at an average cost of $14.19 per share, with a total value of $212,850.00. Following the transaction, the chief executive officer now owns 260,418 shares in the company, valued at approximately $3,695,331.42. The acquisition was disclosed in a filing with the SEC, which is available at this link. Company insiders own 3.60% of the company’s stock.
Institutional investors have recently modified their holdings of the stock. Financial Gravity Wealth Inc. bought a new stake in AngioDynamics in the 2nd quarter valued at about $33,000. Venturi Wealth Management LLC bought a new stake in AngioDynamics in the 3rd quarter valued at about $34,000. Nisa Investment Advisors LLC increased its position in AngioDynamics by 100.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,200 shares of the medical instruments supplier’s stock valued at $43,000 after buying an additional 1,100 shares in the last quarter. Bank of Montreal Can increased its position in AngioDynamics by 78.7% in the 2nd quarter. Bank of Montreal Can now owns 6,981 shares of the medical instruments supplier’s stock valued at $138,000 after buying an additional 3,075 shares in the last quarter. Finally, Pacer Advisors Inc. bought a new stake in AngioDynamics during the 3rd quarter worth approximately $141,000. 98.79% of the stock is owned by institutional investors and hedge funds.
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.